PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Bulevirtide→

Bulevirtide PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2012558-47-1
Molecular formula
C248H355N65O72
Molecular weight
5399 g/mol
Drug class
Hepatitis D virus (HDV) entry inhibitormyristoylated pre-S1 lipopeptide
Mechanism of action
Binds the sodium taurocholate cotransporting polypeptide (NTCP) receptor on hepatocytes, blocking entry of hepatitis B and D viruses into liver cells. It prevents new infection of hepatocytes but does not directly eliminate intracellular viral genomes.
Indications / reported uses
  • Treatment of chronic hepatitis D virus (HDV) infection in adults with compensated liver disease, with or without concomitant HBV infection, under the EU-authorised Hepcludex indication; use in combination with HBV management as directed by specialist product information

Sources: EMA EPAR — Hepcludex (bulevirtide) · EMA product information — Hepcludex · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Bulevirtide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Bulevirtide Permitted Daily Exposure (PDE) report (the Bulevirtide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Bulevirtide Occupational Exposure Limit (OEL) report (the Bulevirtide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.